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1. Introduction 
This chapter deals with two major challenges facing PET neuroimaging of depressive 
disorders: determining the neurobiology of depressive disorders and inventing suitable 
positron-emitting radioligands for exploring molecular aspects of brain function. Over the 
years, PET neuroimaging of depressive disorder has focused almost exclusively on 
monoaminergic neurotransmission, but judging from recent reports, those studies have 
failed to demonstrate reliable links between either serotonergic or dopaminergic 
mechanisms and depressive disorders. Today, disturbances in numerous other 
neurobiological processes are thought to cause depressive disorder, but we lack PET 
radioligands to test most modern hypotheses in the living human brain. Thus, the future 
success of PET neuroimaging of depressive disorders depends on advances in neuroscience 
concerning molecular neurobiology and on advances in radiochemistry for the synthesis of 
novel positron-emitting molecules to test hypotheses on the neurobiology of depressive 
disorders. Success in PET neuroimaging of depressive disorders is expected to provide 
insight toward better prevention and treatment of these disabling conditions.  
 
2. Depressive disorders 
Depression is a severe, disabling, and sometime fatal illness. Symptoms of depression 
include a mental state of hopelessness, sleep disturbance, altered appetite, lack of energy, 
concentration difficulties, low self-esteem, self-destructive behavior, painful bodily 
sensations, and suicidal ideation. Needless to say, depressive disorders require prompt 
attention and appropriate care. A major current issue in psychiatry is the lack effective 
treatments to relieve the symptoms of depression in many sufferers (Berlim et al. 2008;Rush 
et al. 2003a;Rush et al. 2009). Hopefully, further studies of neurobiological mechanisms in 
depressive disorders will eventually lead to more effective antidepressant treatments. That 
hope has motivated many studies of molecular mechanisms in depression using positron 
emission tomography (PET).  
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3. Principles of PET neuroimaging 
PET neuroimaging is a challenging technology. It requires rapid synthesis of highly-purified 
positron-emitting radioligands of high specific activity, intravenous injection of radioactive 
compound often with arterial blood sampling in partially immobilized subjects, 3-
dimensional registration of photon emissions from the target organ over time, and 
computerized computations of kinetic parameters. The kinetic parameter used most often to 
describe the outcome of PET neuroimaging, namely the binding potential, is a complex 
entity composed of three factors: the number of receptors that are available for binding by 
the PET radioligand, the affinity of the available receptors toward the PET radioligand , and 
the concentration of molecules other than the PET radioligand that bind to those receptors 
(Dunlop and Nemeroff 2007;Laruelle 2000;Lammertsma 2002). The binding potential is an 
estimate that reflects a series of molecular events, and its value depends on the kinetic 
model selected for the data analysis. The contribution of individual factors to the binding 
potential cannot be determined by the single-scan design used in most PET studies of 
depression. Thus, the complexity of both depression and PET sets limits on the 
interpretation of findings.  
Most PET studies of depressive disorders have been based on the monoamine hypothesis 
(Schildkraut et al. 1968;Schildkraut and Kety 1967), despite the clear-cut need for exploring 
other strategies (Hindmarch 2002;Berton and Nestler 2006;Pittenger and Duman 
2008;Paschos et al. 2009;Covington, III et al. 2010;Wegener and Volke 2010). Here, we first 
review recent molecular PET reports on depressive disorders in humans. Next, we discuss 
challenges for PET in studying in humans the molecular basis of depressive disorders. Then, 
we outline the need for suitable positron-emitting radioligands for testing modern 
hypotheses on the causes and consequences of depressive disorders. Clearly, there are a 
number of major challenges facing those who care to know the molecular basis of these 
disabling and sometimes fatal diseases. 
 
4. Recent PET studies of serotonin in depressive disorders 
Serotonergic neurotransmission has received most attention in studies of depression 
(Nemeroff and Owens 2009;Owens and Nemeroff 1994). We find, however, that PET studies 
have not provided consistent findings of a causal link between serotonergic dysfunction and 
the severity of depressive disorders. Ten PET studies published in recent years have used 
[11C]McNeil 5652 or [11C]DASB to assess the serotonin transporter in depressed subjects and 
healthy controls. Four of those studies, plus a data re-analysis, noted less binding by the 
serotonin transporter in brain regions of depressed subjects (Miller et al. 2008;Oquendo et al. 
2007;Parsey et al. 2006a;Reimold et al. 2008;Miller et al. 2009b), four studies found more 
binding by the serotonin transporter in depressed subjects (Reivich et al. 2004;Cannon et al. 
2006b;Cannon et al. 2007;Boileau et al. 2008), and two studies found no difference between 
depressed subjects and healthy controls in binding by serotonin transporters in brain 
regions (Meyer et al. 2004;Bhagwagar et al. 2007).  
Discrepancies are also apparent in the outcome of recent PET studies carried out with 
[11C]WAY-100635 or [18F]FCWAY to assess serotonin type 1A receptors in depressed 
subjects and healthy controls. Here, five studies noted less binding by serotonin type 1A 
receptors in brain regions of depressed subjects (Bhagwagar et al. 2004;Meltzer et al. 
2004;Hirvonen et al. 2008;Drevets et al. 2007;Theodore et al. 2007), one study reported no 
difference between depressed subjects and healthy controls in binding by serotonin type 1A 
receptors (Mickey et al. 2008), while more binding by serotonin type 1A receptors was found 
in three studies of depressed subjects or remitted, depressed subjects compared with healthy 
controls, with no correlation between receptor binding and depression severity (Parsey et al. 
2006b;Miller et al. 2009a;Sullivan et al. 2009). In addition, neither antidepressant treatment 
including ECT nor induction of depression by depletion of tryptophan affected binding by 
serotonin type 1A receptors in brain regions (Moses-Kolko et al. 2007;Praschak-Rieder et al. 
2004;Saijo et al. 2010). These findings clearly challenge the notion that alterations of 
serotonergic functions are causally linked with either depressive disorders or antidepressant 
efficacy.  
Serotonin type 2 receptors have also been studied by PET in recent years in relation to 
depressive disorders. Two closely-related studies used [18F]altanserin for PET and noted less 
hippocampal binding in depressed subjects than in healthy controls (Mintun et al. 
2004;Sheline et al. 2004). In contrast, two other PET studies used either [11C]MDL 100,907 or 
[18F]setoperone to assess serotonin type 2 receptors and noted more binding in depressive 
subjects than in healthy controls (Bhagwagar et al. 2006;Meyer et al. 2003). In our view, PET 
studies with the radioligands that are currently available for assessing serotonergic 
functions in the living human brain have failed to provide conclusive evidence for aberrant 
serotonergic mechanisms in depressive disorders. We have noted, however, that receptor 
occupancy of serotonin transporters can be assessed reliably by PET with [11C]DASB or 
[11C]McNeil 5652 (Voineskos et al. 2007;Miller et al. 2008). Perhaps studies of receptor 
occupancy before and during antidepressant therapies can provide a means of determining 
whether treatment-resistance stems from inadequate receptor blockade.  
Monoamine oxidase has also received attention in PET studies of depressive disorders. One 
study used [11C]harmine, a reversible inhibitor of type A MAO, for PET scanning in order to 
see whether the activity of that enzyme differs between depressed patients and healthy 
subjects (Meyer et al. 2006a). More binding of [11C]harmine was noted in brain regions of 
depressed patients than in healthy controls, but no correlation was found between clinical 
variables and PET findings in the patients. A lack of correspondence between clinical 
condition of patients and degree of binding of [11C]harmine in brain regions was also 
observed in a recent follow-up PET study of type A MAO in depressive disorders; an 
elevated distribution volume of the PET radioligand persisted in patients despite symptom-
reduction during antidepressant drug treatment (Meyer et al. 2009a).   
 
5. Recent PET studies of dopamine in depressive disorders 
Dopaminergic neurotransmission is thought to play a role in depression, perhaps via defects 
in central reward systems (Randrup and Braestrup 1977;Spanagel and Weiss 1999). Several 
PET radioligands have been used in recent years for probing dopaminergic mechanisms in 
depressed humans. [18F]Fluoro-L-dopa is used routinely for assessing dopamine synthesis 
by PET in Parkinson’s disease (Takikawa et al. 1994), and it showed reduced striatal uptake 
in depressed subjects with retarded movement (Bragulat et al. 2007). Certain dopamine 
receptors have also been examined by PET in recent years in depressed subjects. Dopamine 
D1 receptors were assessed by [11C]SCH 23,390 or [11C]NNC-112 in two PET studies of 
depression (Dougherty et al. 2006;Cannon et al. 2008), and both reports found less binding 
in striatal regions of depressed subjects than of healthy controls. Dopamine D2/3 receptors 
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have been assessed in five PET studies using either [11C]raclopride or [11C]FLB 457 in 
depressed subjects and healthy controls; one study noted more striatal binding by dopamine 
D2/3 receptors in depressed subjects (Meyer et al. 2006b), another study found less dopamine 
D2/3 receptor binding in depression (Montgomery et al. 2007), and three studies showed no 
difference between depressed and healthy subjects in dopamine D2/3 receptor binding in 
brain regions (Kuroda et al. 2006;Montgomery et al. 2007;Busto et al. 2009). The transport of 
dopamine as well as noradrenaline from the synaptic cleft into presynaptic terminals was 
assessed by PET using [11C]RTI-32 in 20 Parkinson patients, some of which were depressed 
(Remy et al. 2005). Less transporter binding was noted in brain regions of depressed 
Parkinson patients than of non-depressed patients with Parkinson’s disease. In our view, a 
consistent picture of causal relationships between dopaminergic disturbances and 
depression has failed to appear from PET studies carried out with the positron-emitting 
radioligands that are currently available for use in humans, except perhaps for movement 
disorders of depressed subjects.  
 
6. Recent PET neuroimaging of non-serotonergic and non-dopaminergic 
mechanisms in depressive disorders. 
Relatively few PET studies of depressive disorders have been reported recently on 
molecular mechanisms unrelated to serotonergic and dopaminergic neurotransmission.  
In one study, [11C]doxepin was used to see whether human depression depends on 
histaminergic mechanisms (Kano et al. 2004). The binding potential of the PET radioligand 
in some brain regions was lower in depressed patients than in healthy subjects and was 
correlated negatively to the patient’s self-rated depression severity. In another PET study, 
the role of cholinergic processes in major depressive disorder was studied using [18F]FP-
TZTP (Cannon et al. 2006a).  The depressed patients had a diagnosis of either recurrent 
major depressive disorder or bipolar disorder. [18F]FP-TZTP binding in cortical brain 
regions and white matter was lower in bipolar depressed patients than in healthy subjects 
and was correlated negatively to depression severity.  A third PET study used 2-[18F]FA-
85380 to look at cholinergic function and self-rated symptoms of depression in patients with 
Parkinson disease (Meyer et al. 2009b).  Although none of the Parkinson patients met 
standard criteria for major depressive disorder (Schrag et al. 2007;Bech 1984), negative 
correlations were noted between self-rated depression scores and binding of the PET 
radiotracer in several cortical regions. Another PET study of subjects with only mild self-
rated symptoms of depression used [18F]FDDNP to explore possible correlations with 
aggregates of amyloid and tau proteins in brain regions (Lavretsky et al. 2009). Subjects with 
mild cognitive impairment showed a positive correlation between self-rated depression 
scores and radioligand binding in medial temporal lobe.  
 
7. Challenges for PET neuroimaging of depressive disorders  
Molecular tools currently available for PET neuroimaging in humans assess primarily 
monoaminergic receptors on surface of brain cells. As a result, most PET neuroimaging 
studies of depressive disorder focus on some aspect of the monoamine hypothesis. In our 
view, such PET studies have neither proved nor refuted conclusively any aspect of the 
monoamine hypothesis for depression (Schildkraut and Kety 1967;Asberg et al. 1976;Meltzer 
and Lowy 1987). While that monoamine hypothesis has been fruitful in certain ways, 
advances in neurobiology and neuropsychopharmacology have introduced a variety of 
additional molecular mechanisms into research on depressive disorders (Figure 1). Today, 
depression is viewed as the result of multiple neurobiological processes including 
disturbances of gene expression, intracellular signaling, cytokines and neurotropic agents 
(Tanis and Duman 2007;Berton and Nestler 2006;Krishnan and Nestler 2008;Maes 
2008;Pittenger and Duman 2008). In our view, the success of PET scanning in determining 
the role of diverse neurobiological processes in depression will depend heavily on the 
invention of appropriate molecular tools, in the form of positron-emitting radioligands, for 
testing directly, in the living human brain, ever-changing hypotheses on causal connections 
between neuromolecular processes and the symptoms and severity of depressive disorders.  
PET neuroimaging has been unable to pinpoint neurobiological defects in the brain of 
humans suffering from depressive disorders. This is perhaps not surprising, given the 
limited number of suitable positron-emitting radioligands that are currently available for 
PET studies of neurobiological processes in humans. Despite more than two decades of 
research, inconsistent findings have been obtained between molecular PET studies of 
depressive disorders, with few replication attempts. An important challenge facing PET 
neuroimaging of depressive disorders resides, therefore, in determining which aspects of 
depressive disorders to study next. We propose that particular attention be given to 
studying antidepressant non-response by PET, because that condition remains a major 
challenge for medical and social resources, with 25 – 50% of people suffering from major 
depressive disorder never recovering fully (Rush et al. 2003b;Rush et al. 2008;Fava 
2003;Petersen et al. 2005;Berlim and Turecki 2007). Severe aberrations in molecular 
mechanisms at multiple cerebral sites may be involved in antidepressant non-response 
(Krishnan and Nestler 2008;Berton and Nestler 2006;Ressler and Mayberg 2007;Drevets et al. 
2008). Success in determining by PET the neurobiological basis of antidepressant non-
response can be expected to provide an improved understanding of depressive disorders 
and point to more effective ways of treating them.    
The richness of human emotions, thoughts, and actions along with the complexity of 
molecular events in the human brain caution, however, against expectations of rapid 
progress in discovering by PET neuroimaging an improved diagnostic system or a panacea 
for depression (MacQueen 2009). This brings us to another challenge for PET neuroimaging 
of depressive disorders, namely that of integrating rapid advances in neuroscience into 
suitable positron-emitting radioligands and PET research designs. In view of the 
heterogeneous nature of depressive disorders (Berlim and Turecki 2007;Parker 2000;Pae et 
al. 2009;Thase 2009), multiple molecular pathways may cause symptoms of the disease. 
Some of the pathways that may be causally connected to depressive disorders include genes 
that encode presynaptic vesicular proteins, plasma membrane receptors, intracellular 
signaling molecules, proteins that regulate the actin cytoskeleton, and the transcriptional 
regulatory machinery (Covington, III et al. 2010). Additional molecular pathways thought to 
be either causative or curative of depression include neuroplasticity, neuropeptides, and 
nitric oxide synthase (Pittenger and Duman 2008;Paschos et al. 2009;Wegener and Volke 
2010). Clearly, responding promptly to ever-changing notions on molecular pathways of 
depressive disorders constitutes a major challenge for PET neuroimaging.  
Another challenging issue for PET neuroimaging of depressive disorders concerns financial 
support of research. Compared with the costs of brain diseases in the US and Europe 
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(Sobocki et al. 2006;Greenberg et al. 2003;Russell et al. 2004), national funding of molecular 
brain imaging is miniscule. In Europe, for example, the total annual cost of depression in 
2004 was 120 billion Euro, for a population of 466 million with at least 21 million affected 
residents (Sobocki et al. 2006), making depression the most costly brain disorder. In contrast, 
recent annual funding for molecular brain imaging of depressive disorders can be estimated 
at only 0.001 – 0.003 billion Euro, which is 100,000 times less than the annual cost of the 
disease. Without substantial funding, molecular brain imaging by PET may continue to be 
severely handicapped in providing reliable findings on molecular causes, consequences, and 
cures of depressive disorders.  
An additional challenge for PET neuroimaging of depressive disorders concerns the 
invention of appropriate research strategies for testing multiple hypotheses on molecular 
mechanisms in the living brain. At present, two opposing strategies characterize research in 
this field. One strategy advocates the use of positron-emitting radioligands with marked 
selectivity and high affinity for a single, specific neuronal macromolecule such as a 
monoamine receptor or enzyme.  That approach has, in fact, been used in the majority of 
PET studies on molecular mechanisms in depression and may reflect the assumption that 
depressive disorders are caused by a dysfunction of a single molecular mechanism. The 
other strategy advocates the use of positron-emitting radioligands with affinities for several 
neuronal macromolecules. This approach may rest on the assumption that depressive 
disorders are caused by disturbances in any number of multiple molecular pathways. 
Recently, we followed the notion of multiple molecular pathways in a PET study of 
treatment-resistant depression (Smith et al. 2009). Using [11C]mirtazapine, a positron-
emitting radioligand of an antidepressant drug affecting several receptor systems (Millan 
2006;Millan 2009;Smith et al. 2007), we studied by PET a group of depressed subjects who 
had failed to benefit from at least two antidepressant treatments (Smith et al. 2009). All 
subjects had received no antidepressant medication for at least 2 months before the study. 
We found that binding potentials of [11C]mirtazapine in cerebral cortical regions were, in 
general, lower in depressed nonresponders than in healthy controls, while removal rates of 
[11C]mirtazapine were generally higher in diencephalic regions of depressed nonresponders 
than in healthy controls. In keeping with the notion that depressive disorders are 
heterogeneous (Berlim and Turecki 2007;Parker 2000;Pae et al. 2009;Thase 2009), we noted 
that the binding of [11C]mirtazapine in brain regions of some of the depressed, 
antidepressant-nonresponders was well-within the normal range, whereas reduced regional 
binding of [11C]mirtazapine was noted in other depressed subjects. A challenge for 
additional PET studies with [11C]mirtazapine is to see whether the procedure can provide a 
neuromolecular-screening devise that can distinguish between neurobiologically-distinct 
subgroups of depressed, antidepressant-nonresponders.  
One of the most formidable challenges for PET neuroimaging of depressive disorders relates 
to the blood-brain-barrier (BBB). The BBB is a limiting factor for PET studies of 
neuromolecular processes in the living human brain because it both restricts the passage of 
endogenous and foreign substances into the brain and expels many substances rapidly from 
the brain (Beduneau et al. 2008;Gjedde et al. 2000;Halldin et al. 2001;Kreuter 2001;Laruelle et 
al. 2002;Misra et al. 2003;Tosi et al. 2008). Thus, failure to traverse the BBB in sufficient 
quantities and/or to remain in brain tissue for a sufficient duration in the course of a PET-
scanning session has caused many candidate radioligands to be discarded. PET 
neuroscientists will need to devise ways of improving the passage of novel positron-
emitting radioligands across the BBB for binding to molecular targets within the central 
nervous system. One possibility that may deserve close attention in the time ahead concerns 
the use of nanoparticles in PET neuroimaging. Some nanoparticles have already been shown 
to markedly enhance the level of certain drugs in the central nervous system (Gelperina et 
al. 2009;Kreuter 2002;Vergoni et al. 2009), indicating a potential role of nanoparticles as 
carrier-molecules for ushering novel PET radioligands to their neurobiological targets.  
 
8. Challenges for PET radiochemistry 
The synthesis and development of radiopharmaceuticals for PET is a complicated and 
extremely challenging process. The main challenge of using the short-lived PET 
radioisotopes carbon-11 (t1/2 = 20.4 min), fluorine-18 (t1/2 = 110 min), nitrogen-13 (t1/2 = 9.97 
min) or oxygen-15 (t1/2 = 2.04 min) for the synthesis of radiopharmaceuticals is that of time 
(Fowler and Wolf 1997). The short half-lives of these radioisotopes imposes severe time 
restrictions when preparing radiolabelled compounds for PET.  Such short time periods 
limit the range of synthetic strategies that are available to obtain target radiolabelled 
compounds, confining them to chemical reactions and processes that are on the order of 
seconds and minutes rather than hours.  Many PET radiolabelling procedures are therefore 
limited to only one or two distinct chemical steps with the introduction of the PET 
radioisotope as late in the radiosynthesis as possible.  The radioisotopes 13N and 15O are of 
limited applicability for imaging receptor-related processes of the CNS because their short 
half-lives prohibit the synthesis of complex tracer molecules and are generally not 
commensurate with the time frames required for monitoring ligand-receptor based 
processes. 11C and 18F are therefore the most commonly used radioisotopes in PET for 
imaging neuroreceptor processes, having half-lives that are long enough to enable multi-
step synthesis of quite complex radioligands in addition to being appropriate for monitoring 
ligand-receptor processes.  The choice of which radioisotope, 11C or 18F, to use depends on a 
number of decisive factors. Firstly, the structure of the target molecule.  For example, does it 
have fluorine atom and would introducing an 18F adversely affect its biological properties? 
Secondly, the ease of synthesis.  Can the target molecule be synthesised using available 
chemical techniques and are the appropriate 18F or 11C precursors available for reaction?  
There may be an obvious advantage in using one radioisotope over the other in terms of 
radiochemical yield, specific activity or speed of labelling. Thirdly, the time frame of the 
biological process under investigation; 18F may be a more appropriate isotope for the 
investigation of longer biological processes such as protein synthesis.   
Carbon is present in all natural products and almost every artificially synthesised drug-like 
compound.  The replacement of a naturally abundant 12C atom with that of a positron-
emitting 11C isotope results in 11C-labeled molecules that will have essentially identical 
chemical and biological properties of the parent compound.  This is a hugely important 
feature since it removes any doubts about the effect of introducing an artificial exogenous 
radioisotope (e.g. 18F) or tag (e.g. [Ga-DOTA] complex) into the parent molecule which may 
affect its biological behaviour. Although the short 20 min half-life of 11C precludes long 
multistep syntheses, a wide range of chemical reactions have been developed for 
synthesising 11C labelled compounds (Miller et al. 2008). In comparison, 18F has a 
considerably longer half-life of 110 min which permits longer and more complex 
radiosynthetic strategies in addition to allowing the transportation of doses to scanning sites 
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(Sobocki et al. 2006;Greenberg et al. 2003;Russell et al. 2004), national funding of molecular 
brain imaging is miniscule. In Europe, for example, the total annual cost of depression in 
2004 was 120 billion Euro, for a population of 466 million with at least 21 million affected 
residents (Sobocki et al. 2006), making depression the most costly brain disorder. In contrast, 
recent annual funding for molecular brain imaging of depressive disorders can be estimated 
at only 0.001 – 0.003 billion Euro, which is 100,000 times less than the annual cost of the 
disease. Without substantial funding, molecular brain imaging by PET may continue to be 
severely handicapped in providing reliable findings on molecular causes, consequences, and 
cures of depressive disorders.  
An additional challenge for PET neuroimaging of depressive disorders concerns the 
invention of appropriate research strategies for testing multiple hypotheses on molecular 
mechanisms in the living brain. At present, two opposing strategies characterize research in 
this field. One strategy advocates the use of positron-emitting radioligands with marked 
selectivity and high affinity for a single, specific neuronal macromolecule such as a 
monoamine receptor or enzyme.  That approach has, in fact, been used in the majority of 
PET studies on molecular mechanisms in depression and may reflect the assumption that 
depressive disorders are caused by a dysfunction of a single molecular mechanism. The 
other strategy advocates the use of positron-emitting radioligands with affinities for several 
neuronal macromolecules. This approach may rest on the assumption that depressive 
disorders are caused by disturbances in any number of multiple molecular pathways. 
Recently, we followed the notion of multiple molecular pathways in a PET study of 
treatment-resistant depression (Smith et al. 2009). Using [11C]mirtazapine, a positron-
emitting radioligand of an antidepressant drug affecting several receptor systems (Millan 
2006;Millan 2009;Smith et al. 2007), we studied by PET a group of depressed subjects who 
had failed to benefit from at least two antidepressant treatments (Smith et al. 2009). All 
subjects had received no antidepressant medication for at least 2 months before the study. 
We found that binding potentials of [11C]mirtazapine in cerebral cortical regions were, in 
general, lower in depressed nonresponders than in healthy controls, while removal rates of 
[11C]mirtazapine were generally higher in diencephalic regions of depressed nonresponders 
than in healthy controls. In keeping with the notion that depressive disorders are 
heterogeneous (Berlim and Turecki 2007;Parker 2000;Pae et al. 2009;Thase 2009), we noted 
that the binding of [11C]mirtazapine in brain regions of some of the depressed, 
antidepressant-nonresponders was well-within the normal range, whereas reduced regional 
binding of [11C]mirtazapine was noted in other depressed subjects. A challenge for 
additional PET studies with [11C]mirtazapine is to see whether the procedure can provide a 
neuromolecular-screening devise that can distinguish between neurobiologically-distinct 
subgroups of depressed, antidepressant-nonresponders.  
One of the most formidable challenges for PET neuroimaging of depressive disorders relates 
to the blood-brain-barrier (BBB). The BBB is a limiting factor for PET studies of 
neuromolecular processes in the living human brain because it both restricts the passage of 
endogenous and foreign substances into the brain and expels many substances rapidly from 
the brain (Beduneau et al. 2008;Gjedde et al. 2000;Halldin et al. 2001;Kreuter 2001;Laruelle et 
al. 2002;Misra et al. 2003;Tosi et al. 2008). Thus, failure to traverse the BBB in sufficient 
quantities and/or to remain in brain tissue for a sufficient duration in the course of a PET-
scanning session has caused many candidate radioligands to be discarded. PET 
neuroscientists will need to devise ways of improving the passage of novel positron-
emitting radioligands across the BBB for binding to molecular targets within the central 
nervous system. One possibility that may deserve close attention in the time ahead concerns 
the use of nanoparticles in PET neuroimaging. Some nanoparticles have already been shown 
to markedly enhance the level of certain drugs in the central nervous system (Gelperina et 
al. 2009;Kreuter 2002;Vergoni et al. 2009), indicating a potential role of nanoparticles as 
carrier-molecules for ushering novel PET radioligands to their neurobiological targets.  
 
8. Challenges for PET radiochemistry 
The synthesis and development of radiopharmaceuticals for PET is a complicated and 
extremely challenging process. The main challenge of using the short-lived PET 
radioisotopes carbon-11 (t1/2 = 20.4 min), fluorine-18 (t1/2 = 110 min), nitrogen-13 (t1/2 = 9.97 
min) or oxygen-15 (t1/2 = 2.04 min) for the synthesis of radiopharmaceuticals is that of time 
(Fowler and Wolf 1997). The short half-lives of these radioisotopes imposes severe time 
restrictions when preparing radiolabelled compounds for PET.  Such short time periods 
limit the range of synthetic strategies that are available to obtain target radiolabelled 
compounds, confining them to chemical reactions and processes that are on the order of 
seconds and minutes rather than hours.  Many PET radiolabelling procedures are therefore 
limited to only one or two distinct chemical steps with the introduction of the PET 
radioisotope as late in the radiosynthesis as possible.  The radioisotopes 13N and 15O are of 
limited applicability for imaging receptor-related processes of the CNS because their short 
half-lives prohibit the synthesis of complex tracer molecules and are generally not 
commensurate with the time frames required for monitoring ligand-receptor based 
processes. 11C and 18F are therefore the most commonly used radioisotopes in PET for 
imaging neuroreceptor processes, having half-lives that are long enough to enable multi-
step synthesis of quite complex radioligands in addition to being appropriate for monitoring 
ligand-receptor processes.  The choice of which radioisotope, 11C or 18F, to use depends on a 
number of decisive factors. Firstly, the structure of the target molecule.  For example, does it 
have fluorine atom and would introducing an 18F adversely affect its biological properties? 
Secondly, the ease of synthesis.  Can the target molecule be synthesised using available 
chemical techniques and are the appropriate 18F or 11C precursors available for reaction?  
There may be an obvious advantage in using one radioisotope over the other in terms of 
radiochemical yield, specific activity or speed of labelling. Thirdly, the time frame of the 
biological process under investigation; 18F may be a more appropriate isotope for the 
investigation of longer biological processes such as protein synthesis.   
Carbon is present in all natural products and almost every artificially synthesised drug-like 
compound.  The replacement of a naturally abundant 12C atom with that of a positron-
emitting 11C isotope results in 11C-labeled molecules that will have essentially identical 
chemical and biological properties of the parent compound.  This is a hugely important 
feature since it removes any doubts about the effect of introducing an artificial exogenous 
radioisotope (e.g. 18F) or tag (e.g. [Ga-DOTA] complex) into the parent molecule which may 
affect its biological behaviour. Although the short 20 min half-life of 11C precludes long 
multistep syntheses, a wide range of chemical reactions have been developed for 
synthesising 11C labelled compounds (Miller et al. 2008). In comparison, 18F has a 
considerably longer half-life of 110 min which permits longer and more complex 
radiosynthetic strategies in addition to allowing the transportation of doses to scanning sites 
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several hours away. The key concern, alluded to above, of introducing an 18F radioisotope 
into a molecule is the unknown effects the fluorine atom may have on the biological 
properties of the newly labelled compound. Radiosynthesis with 18F may be classified into 
two areas: (i) direct fluorination, where the 18F isotope is introduced into the target molecule 
in one chemical step, and (ii) indirect fluorination which requires a multi-step synthesis for 
the preparation of so-called 18F prosthetic groups that are then further reacted to give the 
target molecule. Considerable effort has been devoted to the development of these small and 
reactive 18F prosthetic groups for the rapid labelling of a range of 18F molecules. In recent 
years the development of rapid ‘click chemistry’ methods continues to generate much 
interest in this area (Glaser and Robins 2009).   
Some of the challenges within PET radiochemistry are evidently more obvious than others 
and relate to the technical challenges associated with the fast, efficient and safe handling of 
short-lived radioactive material. The production of a pharmaceutical-quality radiotracer 
sample ready for injection requires the synthesis, purification, and analysis to be complete, 
generally, within three half-lives of the radioisotope in order to provide enough 
radioactivity for a reliable scan. In the case of a 11C radiosynthesis, this would be within 60 
min from the end of bombardment. The need for such fast reactions and processes has lead, 
not only to new chemical methodologies, but to technological advancements in the 
development of fully automated and programmable synthesis units for performing and 
processing radiosynthetic reactions. New technologies such as microwave cavities (Elander 
et al. 2000), microfluidic reactors (Miller 2009), and solid-phase synthesis methods (Marik et 
al. 2006) have been adapted to enhance the speed, reproducibility, and efficiency of 
radiolabelling reactions.   
Other challenges are more subtle and include the unusual scale of PET labelling reactions 
where the cold precursor in the reaction is often in huge excess (>1000 fold) compared with 
the radiolabelled compound. This can lead to unpredictable reaction kinetics and the 
formation of unwanted by-products from competing side reactions. There is often a desire to 
improve radiochemical yields (RCY) and to obtain high specific activities from labelling 
reactions. Although high RCYs are not always essential, they do provide a very useful 
measure of the efficiency of the radiolabelling procedure.  The requirement of high specific 
activity, on the other hand, is often essential for the study of neuroreceptors such as those 
associated with depressive disorders. Specific activities of a radiolabelled compound for a 
PET study of neuroreceptors are typically required to be in the order of 50–500 GBq µmol-1.  
The requirement of high specific activities is most apparent if the radioligand has a high 
affinity for a receptor. Radiotracers produced with low specific activity will result in poor 
PET images owing to the rapid saturation of the binding sites by the proportionately higher 
amount of non-radioactive ligand.  The production of radiotracers with high specific activity 
is therefore highly desirable but can be challenging and depends on the radioisotope 
selected for the radiosynthesis, choice of synthetic precursor material and radiosynthetic 
labelling route. Take, for example, the selective 5-HT1A receptor antagonist WAY-100635 
which can be radiolabelled using 11C in the carbonyl position to give [carbonyl-11C]WAY-
100635 (figure 2). This is usually achieved via the two-step reaction of 11CO2 with 
cyclohexylmagnesium chloride sequentially followed by addition of thionyl chloride to give 
the reactive [carbonyl-11C]cyclohexyl acid chloride. Reaction of [carbonyl-11C]cyclohexyl acid 
chloride with the WAY-100634 amine precursor generates the desired [carbonyl-11C]WAY-
100635 (McCarron et al. 1996). One of the key challenges with the synthesis of [carbonyl-
11C]WAY-100635 is the exclusion of atmospheric 12CO2 which poses a significant risk of 
contaminating the reaction at the initial first step. Without due care, contamination from 
atmospheric 12C results in an undesirably low specific radioactivity, and consequently poor 
PET images.   
The labelling position of radioisotope on the ligand is also a key consideration, and can pose 
significant challenges. Two key questions should be asked regarding labelling position, (i) is 
it viable, synthetically, to radiolabel in the position that we desire? and (ii) will the labelling 
position be metabolically stable? An understanding of the metabolic fate of a radiotracer can 
be vitally important in the development of a radiotracer and in determining the best 
position to radiolabel. There is usually a choice of positions within the molecule for 
radioisotope labelling, with some positions being more challenging than others. However, 
labelling a molecule in several different positions can yield important metabolic information 
about the fate of the molecule in vivo and can be useful in determining which labelling 
position is best for imaging. Metabolism of the labelled compound in the body may result in 
undesired labelled metabolites which can give two undesired effects: (i) an enhanced 
unwanted background signal which results in poor quality PET image, and (ii) 
pharmacologically active metabolites that compete with the parent compound for the 
biological target and complicate the interpretation of PET data. The importance of the 
labelling position can be illustrated by past experiences with the 11C labelling of WAY-
100635 radioligand. WAY-100635 can be labelled in either the O-methyl position on the 
phenyl ring via a [11C]methylation reaction or on the carbonyl position as previously 
mentioned above (figure 2). [O-methyl-11C]WAY-100635 was however found to have 
limitations for imaging 5-HT1A receptors in human owing to the formation of the more 
lipophilic descyclohexanecarbonyl ([O-methyl-11C]WAY-100634) metabolite in vivo. This 
metabolite was found to enter the brain much more readily than the parent [O-methyl-
11C]WAY-100635 (Osman et al. 1996) and thus complicate quantification of the 5-HT1A 
receptors by competing with [O-methyl-11C]WAY-100635 for 5-HT1A binding sites and by 
contributing to the non-specific binding signal. In contrast, by selecting to label WAY-100635 
in the carbonyl position (figure 2) significantly improved PET images with much superior 
delineation of 5-HT1A receptors in human brain were obtained (Pike et al. 1996). The reason 
for [carbonyl-11C]WAY-100635 giving better images is due to the metabolism of this 
compound and position of the radioisotope; with the 11C isotope on the carbonyl group 
adjacent to the cyclohexyl ring, in vivo metabolism cleaves the cyclohexyl and 11C carbonyl 
and generates the labelled metabolite [11C]cyclohexanecarboxylic acid which is hydrophilic 
and, therefore, does not readily enter the brain to confound the signal from the parent 
[carbonyl-11C]WAY-100635 molecule.   
Appropriate pharmacodynamic properties, such as high affinities and selectivities for the 
target, are central to characterising the success of a PET radioligand (Passchier et al. 2002). 
The affinity of the probe for the binding site is a key factor that affects the degree of 
nonspecific binding.  Nonspecific binding is a major challenge in the development of 
radioligands and is often cited for the high failure rate of new radioligands. Nonspecific 
binding occurs when the radioligand binds or interacts with a molecular target or tissue 
other than the site of interest.  This could include interactions of the radioligand with 
membrane structures or with receptors which are not under investigation. A high 
proportion of nonspecific binding signal may result in a severe reduction in the PET signal 
contrast when investigating a specific receptor with a radioligand.  The lipophilicity of the 
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several hours away. The key concern, alluded to above, of introducing an 18F radioisotope 
into a molecule is the unknown effects the fluorine atom may have on the biological 
properties of the newly labelled compound. Radiosynthesis with 18F may be classified into 
two areas: (i) direct fluorination, where the 18F isotope is introduced into the target molecule 
in one chemical step, and (ii) indirect fluorination which requires a multi-step synthesis for 
the preparation of so-called 18F prosthetic groups that are then further reacted to give the 
target molecule. Considerable effort has been devoted to the development of these small and 
reactive 18F prosthetic groups for the rapid labelling of a range of 18F molecules. In recent 
years the development of rapid ‘click chemistry’ methods continues to generate much 
interest in this area (Glaser and Robins 2009).   
Some of the challenges within PET radiochemistry are evidently more obvious than others 
and relate to the technical challenges associated with the fast, efficient and safe handling of 
short-lived radioactive material. The production of a pharmaceutical-quality radiotracer 
sample ready for injection requires the synthesis, purification, and analysis to be complete, 
generally, within three half-lives of the radioisotope in order to provide enough 
radioactivity for a reliable scan. In the case of a 11C radiosynthesis, this would be within 60 
min from the end of bombardment. The need for such fast reactions and processes has lead, 
not only to new chemical methodologies, but to technological advancements in the 
development of fully automated and programmable synthesis units for performing and 
processing radiosynthetic reactions. New technologies such as microwave cavities (Elander 
et al. 2000), microfluidic reactors (Miller 2009), and solid-phase synthesis methods (Marik et 
al. 2006) have been adapted to enhance the speed, reproducibility, and efficiency of 
radiolabelling reactions.   
Other challenges are more subtle and include the unusual scale of PET labelling reactions 
where the cold precursor in the reaction is often in huge excess (>1000 fold) compared with 
the radiolabelled compound. This can lead to unpredictable reaction kinetics and the 
formation of unwanted by-products from competing side reactions. There is often a desire to 
improve radiochemical yields (RCY) and to obtain high specific activities from labelling 
reactions. Although high RCYs are not always essential, they do provide a very useful 
measure of the efficiency of the radiolabelling procedure.  The requirement of high specific 
activity, on the other hand, is often essential for the study of neuroreceptors such as those 
associated with depressive disorders. Specific activities of a radiolabelled compound for a 
PET study of neuroreceptors are typically required to be in the order of 50–500 GBq µmol-1.  
The requirement of high specific activities is most apparent if the radioligand has a high 
affinity for a receptor. Radiotracers produced with low specific activity will result in poor 
PET images owing to the rapid saturation of the binding sites by the proportionately higher 
amount of non-radioactive ligand.  The production of radiotracers with high specific activity 
is therefore highly desirable but can be challenging and depends on the radioisotope 
selected for the radiosynthesis, choice of synthetic precursor material and radiosynthetic 
labelling route. Take, for example, the selective 5-HT1A receptor antagonist WAY-100635 
which can be radiolabelled using 11C in the carbonyl position to give [carbonyl-11C]WAY-
100635 (figure 2). This is usually achieved via the two-step reaction of 11CO2 with 
cyclohexylmagnesium chloride sequentially followed by addition of thionyl chloride to give 
the reactive [carbonyl-11C]cyclohexyl acid chloride. Reaction of [carbonyl-11C]cyclohexyl acid 
chloride with the WAY-100634 amine precursor generates the desired [carbonyl-11C]WAY-
100635 (McCarron et al. 1996). One of the key challenges with the synthesis of [carbonyl-
11C]WAY-100635 is the exclusion of atmospheric 12CO2 which poses a significant risk of 
contaminating the reaction at the initial first step. Without due care, contamination from 
atmospheric 12C results in an undesirably low specific radioactivity, and consequently poor 
PET images.   
The labelling position of radioisotope on the ligand is also a key consideration, and can pose 
significant challenges. Two key questions should be asked regarding labelling position, (i) is 
it viable, synthetically, to radiolabel in the position that we desire? and (ii) will the labelling 
position be metabolically stable? An understanding of the metabolic fate of a radiotracer can 
be vitally important in the development of a radiotracer and in determining the best 
position to radiolabel. There is usually a choice of positions within the molecule for 
radioisotope labelling, with some positions being more challenging than others. However, 
labelling a molecule in several different positions can yield important metabolic information 
about the fate of the molecule in vivo and can be useful in determining which labelling 
position is best for imaging. Metabolism of the labelled compound in the body may result in 
undesired labelled metabolites which can give two undesired effects: (i) an enhanced 
unwanted background signal which results in poor quality PET image, and (ii) 
pharmacologically active metabolites that compete with the parent compound for the 
biological target and complicate the interpretation of PET data. The importance of the 
labelling position can be illustrated by past experiences with the 11C labelling of WAY-
100635 radioligand. WAY-100635 can be labelled in either the O-methyl position on the 
phenyl ring via a [11C]methylation reaction or on the carbonyl position as previously 
mentioned above (figure 2). [O-methyl-11C]WAY-100635 was however found to have 
limitations for imaging 5-HT1A receptors in human owing to the formation of the more 
lipophilic descyclohexanecarbonyl ([O-methyl-11C]WAY-100634) metabolite in vivo. This 
metabolite was found to enter the brain much more readily than the parent [O-methyl-
11C]WAY-100635 (Osman et al. 1996) and thus complicate quantification of the 5-HT1A 
receptors by competing with [O-methyl-11C]WAY-100635 for 5-HT1A binding sites and by 
contributing to the non-specific binding signal. In contrast, by selecting to label WAY-100635 
in the carbonyl position (figure 2) significantly improved PET images with much superior 
delineation of 5-HT1A receptors in human brain were obtained (Pike et al. 1996). The reason 
for [carbonyl-11C]WAY-100635 giving better images is due to the metabolism of this 
compound and position of the radioisotope; with the 11C isotope on the carbonyl group 
adjacent to the cyclohexyl ring, in vivo metabolism cleaves the cyclohexyl and 11C carbonyl 
and generates the labelled metabolite [11C]cyclohexanecarboxylic acid which is hydrophilic 
and, therefore, does not readily enter the brain to confound the signal from the parent 
[carbonyl-11C]WAY-100635 molecule.   
Appropriate pharmacodynamic properties, such as high affinities and selectivities for the 
target, are central to characterising the success of a PET radioligand (Passchier et al. 2002). 
The affinity of the probe for the binding site is a key factor that affects the degree of 
nonspecific binding.  Nonspecific binding is a major challenge in the development of 
radioligands and is often cited for the high failure rate of new radioligands. Nonspecific 
binding occurs when the radioligand binds or interacts with a molecular target or tissue 
other than the site of interest.  This could include interactions of the radioligand with 
membrane structures or with receptors which are not under investigation. A high 
proportion of nonspecific binding signal may result in a severe reduction in the PET signal 
contrast when investigating a specific receptor with a radioligand.  The lipophilicity of the 
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tracer molecule is frequently quoted as an important factor in discussions of nonspecific 
binding.  Highly lipophilic molecules are known to interact extensively with the fatty 
residues in membrane bilayers which can prevent penetration of the radioligand into brain 
tissue and therefore prevent it from reaching the intended molecular target. The challenges 
in terms of the design and selection of tracer molecules to image the CNS often involve 
tailoring the lipophilicity of a radioligand. Successful PET CNS radiotracers normally have 
lipophilicities (logP, logarithm of the octanol/water partition coefficient) within an optimal 
logP window of 1.5-3 in order to ensure the passage through the BBB. Although logP values 
are an important indicator in ligand design, they can lead to an oversimplification of ligand 
selection.  A greater understanding of the causes of nonspecific binding at a molecular level 
may be key to achieving higher success rates for radioligand selection. A recent study has 
used computation methods to estimate the interaction energy between candidate molecules 
and phospholipids which can then be used as a predictor for nonspecific binding in vivo 
(Rosso et al. 2008). Results from this study interestingly show that the drug’s interaction 
with the lipid molecule is a better predictor for nonspecific binding than the experimentally 
measured logP value. Further recent work in this area suggests that alternative transport 
mechanisms of drug molecules through biological membranes, which result in the 
chemically activated degradation of the phospholipid membranes, may be related to 
nonspecific binding (Casey et al. 2008).    
 
Concluding remark       
We hope that the challenges described here will inspire scientists to carry out many more 
studies using PET neuroimaging in order to eventually discover new and better procedures 
for diagnosing and treating major depressive disorders. 
 
9. Chemical names  
Altanserin 3-2-4-4-Fluorobenzoyl-1-piperidinylethyl-2,3-dihydro-2-
thioxo-41H-quinazolinone  
DASB  3-Amino-4-[[2-[dimethylaminomethyl] phenyl]thio] 
benzonitrile 
DOTA    1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
Doxepin  3-dibenzo[b,e]oxepin-116H-ylidene-N,N-dimethylpropan-1-
amine  
2-FA-85380    2-fluoro-3-(2[S]-2-azetidinylmethoxy)-pyridine 
FCWAY N-[2-[4-2-Methoxyphenyl-1-piperazinyl]ethyl]-N-2-
pyridinyl-trans-4-fluorocyclohexylcarboxamide 
FDDNP  2-(1-{6-_(2-_fluorine-18_fluoroethyl)(methyl)amino-2-
naphthyl}ethylidene) malononitrile 
FESP 3-2-Fluoroethyl-8-[4-4-fluorophenyl-4-oxobutyl]-1-phenyl-
1,3,8-triazaspiro[4.5]decan-4-one 
FLB 457  5-Bromo-N-[[2S-1-ethyl-2-pyrrolidinyl]methyl]-2,3-
dimethoxybenzamide 
Fluoro-L-dopa    2-Fluoro-5-hydroxy-L-tyrosine 
FP-TZTP  3-3-3-Flouropropylthio-1,2,5-thiadiazol-4-yl-1,2,5,6-
tetrahydro-1-methylpyridine  
Harmine   7-Methoxy-1-methyl-9H-[3,4-b]indole 
McNeil 5652  6S,10bR-1,2,3,5,6,10b-Hexahydro-6-[4-methylthiophenyl]-
pyrrolo[2,1-a]isoquinoline 
MDL 100,907   R-1-[2-4-Fluorophenylethyl]-4-2,3-dimethoxyphenyl-4- 
piperidinemethano  
MPPF  4-Fluoro-N-[2-[4-2-methoxyphenyl-1-piperazinyl]ethyl]-N-
2-pyridinylbenzamide  
α-MTrp    α-Methyl-L-tryptophan 
NNC-112  +-5-7-benzofuranyl-8-chloro-7-hydroxy-3-methyl-2,3,4,5-
tetrahydro-1H-3-benzazapine 
Raclopride  3,5-Dichloro-N-[[2S-1-ethyl-2-pyrrolidinyl]methyl]-2-
hydroxy-6-methoxybenzamide 
RTI-32  Methyl-1R-2-exo-3-exo-8-methyl-3-4-methylphenyl-8-
azabicyclo[3.2.1]octane-2-carboxylate 
SCH 23,390  8-Chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-
benzazepin-7-ol  
Setoperone  6-[2-[4-4-Fluorobenzoyl-1-piperidinyl]ethyl]-2,3-dihydro-7-
methyl-5H-thiazolo[3,2a] pyrimidin-5-one 
WAY-100635 N-[2-[4-2-Methoxyphenyl-1-piperazinyl]ethyl]-N-2-
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tracer molecule is frequently quoted as an important factor in discussions of nonspecific 
binding.  Highly lipophilic molecules are known to interact extensively with the fatty 
residues in membrane bilayers which can prevent penetration of the radioligand into brain 
tissue and therefore prevent it from reaching the intended molecular target. The challenges 
in terms of the design and selection of tracer molecules to image the CNS often involve 
tailoring the lipophilicity of a radioligand. Successful PET CNS radiotracers normally have 
lipophilicities (logP, logarithm of the octanol/water partition coefficient) within an optimal 
logP window of 1.5-3 in order to ensure the passage through the BBB. Although logP values 
are an important indicator in ligand design, they can lead to an oversimplification of ligand 
selection.  A greater understanding of the causes of nonspecific binding at a molecular level 
may be key to achieving higher success rates for radioligand selection. A recent study has 
used computation methods to estimate the interaction energy between candidate molecules 
and phospholipids which can then be used as a predictor for nonspecific binding in vivo 
(Rosso et al. 2008). Results from this study interestingly show that the drug’s interaction 
with the lipid molecule is a better predictor for nonspecific binding than the experimentally 
measured logP value. Further recent work in this area suggests that alternative transport 
mechanisms of drug molecules through biological membranes, which result in the 
chemically activated degradation of the phospholipid membranes, may be related to 
nonspecific binding (Casey et al. 2008).    
 
Concluding remark       
We hope that the challenges described here will inspire scientists to carry out many more 
studies using PET neuroimaging in order to eventually discover new and better procedures 
for diagnosing and treating major depressive disorders. 
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Raclopride  3,5-Dichloro-N-[[2S-1-ethyl-2-pyrrolidinyl]methyl]-2-
hydroxy-6-methoxybenzamide 
RTI-32  Methyl-1R-2-exo-3-exo-8-methyl-3-4-methylphenyl-8-
azabicyclo[3.2.1]octane-2-carboxylate 
SCH 23,390  8-Chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-
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Figure legends 
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